334TiP A phase I trial of niraparib plus anlotinib in advanced solid tumors with homologous recombination repair (HRR) gene mutations

Abstract

Homologous recombination repair (HRR) genes play an important role in DNA double strand damage repair. For tumors with HRR gene mutations, DNA double strand damage may not be repaired by homologous recombination, and PARP inhibitor blocks DNA single strand damage repair, which result in synergistic lethality. HRR gene mutations can be detected in many solid tumors, patients with HRR gene mutations may benefit from PARP inhibitor. Preclinical studies have shown that antiangiogenic drugs can induce hypoxia and increase the sensitivity to PARP inhibitor.